Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (October 2025)
27 slides from Painchek's investor presentation, Oct 31, 2025
Slide 1: September Quarterly 2025
Se ptembe r Q uarterly 20 25 P H I L I P D A F F A S , C EO & M D P A I N C H E K L TD | A S X : PC K 1 |
Slide 2: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 3: Investor Highlights
I NVESTO R H IG HLI G HT S First Mover • PainChek offers the world’s first and only regulatory-cleared AI-enabled SaaS platform to assess pain and Advantage monitor the effect of pain relief in non-communicative populations, administered through a smart phone App • Its SaaS Platform is now contracte
Slide 4: Inflection Points Targeted to Begin CY2025
I NF LEC T I ON P OI NT S T AR GE TE D T O B EGI N C Y20 25 1 2 3 US CONTINUED DIRECT TO PARENT MARKET GROWTH OF MARKET ENTRY OF ENTRY ADULT APP THE INFANT APP • Adult App FDA • Further penetrate • Expand initial market clearance – Aged Care markets entry – App Store & target Q3/Q4 CY2025 (ANZ, UK,
Slide 5: The PainChek Universal App: Quick and Easy Operation
T HE P AI N CH EK ® UNI V ER S A L A PP : Q UIC K AN D EA SY O PER AT IO N AI based micro-facial pain expression analysis: SOFTWARE-AS- • 3 second scan of patient face A-SERVICE MEDICAL DEVICE • Recognises 9 micro-facial expressions indicative of pain ENABLES MOBILE DATA CAPTURE Guided digital quest
Slide 6: Licences, contracted licences, $5.6M contracted ARR & strong pipeline
1 15 , 000 CO NT R AC TE D L IC E NC ES , $5.6M CO NT R AC TED A R R & STR ON G PI PELI N E CON TR ACT ED LIC EN CE S I MP LEM E NT ED • 18% increase in contracted ARR ($5.6M) and 140,000 & T O BE I MP LE ME NT ED 16% increase in actual ARR ($3.4M) over the prior year 120,000 115,770 110,907 100,322
Slide 7: PainChek Qualified Short-Term Pipeline Exceeds 47,000 New Licences
PAINCHEK QUALIFIED SHORT-TERM PIPELINE EXCEEDS 47,000 NEW LICENCES Qualified Contracted Projected Pipeline ARR $5.6M ARR $2.1M ARR $7.7M 180,000 $1.5M ARR 160,000 35,000 140,000 $0.6M ARR 120,000 $2.1M ARR 12,500 100,000 Existing 44,019 pipeline includes 163,270 ANZ, UK & 80,000 $3.5M ARR Canada onl
Slide 8: Consistent Growth in Clinical Utility – World's Largest Pain Database
C ON SIST ENT G RO WTH I N CL IN IC AL UT ILI T Y – WO RLD’S LA RG EST PA IN DA TA BA SE CUMULATIVE NUMBER OF PAINCHEK ASSESSMENTS 16,000,000 Over 14 million global pain 14,661,353 assessments as of September 2025 14,000,000 conducted on the PainChek platform 12,172,377 across more than 150,000 resi
Slide 9: PainChek Analytics – Providing Clinical Insights
P AI NC HEK A NA LYTI C S – P RO VIDI NG C LI NI CA L IN SIG HT S Through PainChek®'s web portal, care managers can access real time dashboard reporting and data analytics, assisting their team in reducing clinical risk while improving their quality of care. Pain data trends are graphed to assist ca
Slide 10: PainChek Adult: FDA De Novo Cleared
PAINCHEK ADULT: FDA DE NOVO CLEARED COMMENCING SALES INTO A$175M ANNUAL LONG TERM CARE MARKET First to Market Competitive Market expansion Differentiator Barriers Pursuing 510K First and only medical Successful 2-year applications for Home device cleared to assess US clinical and AI Care & Hospitals
Slide 11: PainChek Implements First US Long-Term Care Client
P AI NC HE K I MP LE ME N TS F IR S T U S LON G - T ER M C AR E C LIE N T Jewish Home Family, a leading senior care organisation in New Jersey, secured as PainChek’s first US customer. PainChek has been deployed at its flagship location to enhance pain detection & management for residents living wit
Slide 12: PainChek at the AHCA & NCAL Convention & Expo
PAINCHEK AT THE AMERICAN HEALTH CARE ASSOCIATION & NATIONAL CENTER FOR ASSISTED LIVING CONVENTION & EXPO IN LAS VEGAS, 20-23 OCTOBER 2025 KEY TAKEAWAYS: Large client attendance: 3000+ long term care client attendees from across USA PainChek team: Head of US, Canada & Operations plus new US BDM consu
Slide 13: PainChek US Brochures
PAINCHEK US BROCHURES Core Brochure: Introduction to PainChek® and its role in FDA De Novo Pathway: PainChek® & PointClickCare: transforming pain PainChek®’s US clinical Integration overview, assessment in long-term validation and FDA De Novo features and benefits. care. grant. Global Traction: Prov
Slide 14: US Clients Immediate Perceived Benefits of PainChek
US CLIENTS IMMEDIATE PERCEIVED BENEFITS OF PAINCHEK® Face Value of the Long term Care Data Analytics Emerging PainChek App Compliance & AI Opportunities ✔ Fits Long Term Care mission – ✔ Addresses disproportionate ✔ Higher interrater reliability ✔ Growing interest in applying especially valued among
Slide 15: Strong Global Traction in Senior Care Facilities Worldwide
STRONG GLOBAL TRACTION IN SENIOR CARE FACILITIES WORLDWIDE PainChek Canada Europe* (EU) • 300,000 bed (A$20M ARR ) aged care market • Regulatory cleared & patent secured • PCK Adult regulatory cleared & local BDM in • Initial focus 800,000 bed German market – place A$40M ARR • ~1,000 beds licensed -
Slide 16: PainChek Infant
PAINCHEK® INFANT A PainChek Limited Product MAKING INFANT PAIN VISIBLE 16
Slide 17: Making Infant Pain Visible
M AKIN G I NFA NT P AI N VISI BLE • The newest addition to the PainChek family, PainChek Infant, is the world’s first AI-enabled app for instant pain assessment on infants aged 1-12 months • Designed for in-home use by parents or other non-medical carers • Globally, the Infant market opportunity ext
Slide 18: Making Infant Pain Visible
MAKING INFANT PAIN VISIBLE PainChek® Infant app is designed with parents and families in mind, offering a comprehensive user-friendly experience with a range of valuable features including: 3-second facial analysis-based pain assessment Monitoring of historical pain events Documenting treatments, in
Slide 19: PainChek Children's Market Strategy
PAINCHEK CHILDREN’S MARKET STRATEGY – TO ACCESS 400 MILLION PRE-VERBAL CHILDREN WORLDWIDE B2C Consumer B2B HCP B2B HCP Partnership Market Market Market Market Parents Family Daycare Hospital GPs OTs MedTech Pharma Integrations Ambassadors HCP Customers Baby Monitors CHANNELS Social Media Publication
Slide 20: PainChek Infant – Initial Australia Market Performance Update
PAINCHEK INFANT – INITIAL AUSTRALIA MARKET PERFORMANCE UPDATE TOTAL FIRST TIME ACCOUNTS DOWNLOADS DOWNLOADS CREATED CVR 367 324 151 47% (clearer view of true adoption vs reinstall) The team continues to monitor performance at each stage of the funnel, with current priorities focused on improving: •
Slide 21: PainChek Infant – Milestones and Key Updates
PAINCHEK INFANT – MILESTONES AND KEY UPDATES Complete In-progress Next Launched Android in Clinical review of the app Pricing revision the Google Play store by NSW CPR Kids to shift registration towards & development of pain annual & lifetime App release 7 October education material optimised self r
Slide 22: Looking Ahead – Commercialise Infant Technology Globally
LOOKING AHEAD – COMMERCIALISE INFANT TECHNOLOGY GLOBALLY NOW SCALING UP FROM Q1 CALENDAR 2026 ONWARDS Broaden to Continue to markets where Assess EU US Expand in PainChek has market entry Market Australia a presence opportunities Entry • 300k (babies • UK: 700k • CE mark regulatory • FDA follow up t
Slide 23: PainChek Inflection Points Achieved in CY2025
P AI NC HE K I NF L EC TI O N PO IN TS AC HI E V ED I N CY 2 02 5 1 2 3 US CONTINUED DIRECT TO PARENT MARKET GROWTH OF MARKET ENTRY OF ENTRY ADULT APP THE INFANT APP Adult App FDA Further penetrate Expand initial market clearance – Aged Care markets entry – App Store & target Q3/Q4 CY2025 (ANZ, UK,
Slide 24: Battle-Tested Leadership & Deep Clinical Network
BATTLE-TESTED LEADERSHIP & DEEP CLINICAL NETWORK Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam Scott Robertson CEO & Managing Director, Chief Scientific Officer PhD, Head of Operations CFO CTO, MBA, B.Eng. MBA, BSc MPS (Comp. Systems) Philip is a highly accomplished Jeff is a professor i
Slide 25: The Board
T HE B OA RD John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capital. Founder accompl
Slide 26: Corporate Summary
CORPORATE SUMMARY Top shareholders % Financial information Peters Investments Proprietary Ltd 6.4% Share price (30th October 2025) A$0.046 Founders 3.6% Shares on issue 2,091.9m Board & key staff 4.0% Market capitalisation AUD $96.2M Cash (30 September 2025) A$6.3M Debt Nil Unlisted options/performa
Slide 27: September Quarterly
S e p t e m b e r Q u ar t e r l y 2 0 2 5 P H I L I P D A F F A S , C EO & M D P A I N C H E K L TD | A S X : PC K